Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma.

Sorafenib suppressed pDCs function. Given that sorafenib is a currently recommended targeted therapeutic agent against cancer, our results suggest that its immunosuppressive effect on pDCs should be considered during treatment.